Barclays Issues Pessimistic Forecast for Certara (NASDAQ:CERT) Stock Price

Certara (NASDAQ:CERT) had its price target trimmed by Barclays from $14.00 to $12.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Other research analysts have also issued research reports about the stock. JMP Securities restated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. KeyCorp cut their price target on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Friday, September 27th. Finally, Robert W. Baird reduced their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $15.92.

Certara Stock Performance

NASDAQ:CERT traded up $0.03 during mid-day trading on Thursday, hitting $11.02. 818,644 shares of the stock were exchanged, compared to its average volume of 785,217. The firm’s 50-day simple moving average is $11.04 and its 200 day simple moving average is $13.73. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -21.98, a price-to-earnings-growth ratio of 4.88 and a beta of 1.51. Certara has a fifty-two week low of $9.99 and a fifty-two week high of $19.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61.

Certara (NASDAQ:CERT) last announced its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The business had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. During the same period in the previous year, the firm posted $0.10 EPS. The company’s revenue was up 3.2% compared to the same quarter last year. As a group, equities analysts anticipate that Certara will post 0.27 EPS for the current fiscal year.

Insider Buying and Selling at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Certara news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.39% of the company’s stock.

Institutional Investors Weigh In On Certara

Institutional investors have recently added to or reduced their stakes in the business. Capstone Investment Advisors LLC bought a new stake in shares of Certara in the first quarter worth $245,000. GSA Capital Partners LLP bought a new position in shares of Certara during the first quarter worth about $571,000. Texas Permanent School Fund Corp boosted its holdings in Certara by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 93,729 shares of the company’s stock valued at $1,676,000 after acquiring an additional 1,213 shares during the last quarter. TimesSquare Capital Management LLC increased its position in Certara by 2.2% during the 1st quarter. TimesSquare Capital Management LLC now owns 520,390 shares of the company’s stock valued at $9,305,000 after purchasing an additional 11,205 shares during the period. Finally, Sei Investments Co. raised its holdings in Certara by 12.4% during the 1st quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock worth $12,793,000 after purchasing an additional 79,013 shares during the last quarter. 73.96% of the stock is owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.